Insight Molecular Diagnostics Reports 54% Revenue Decline in Q2 2026

Insight Molecular Diagnostics Inc. (iMDx), formerly known as Oncocyte Corporation, reported a significant decline in financial performance for the second quarter of 2026, with net revenue falling to $239,000, a decrease of 54% compared to $518,000 in the same period last year. For the first half of 2026, total revenue was $271,000, down 90% from $2.7 million in the first half of 2025. The company attributed this decline primarily to reduced revenue from its Laboratory Services segment, as it shifts focus towards commercializing its transplant kitted tests. The net loss for the quarter was $11.3 million, compared to a loss of $9.7 million in the prior year, reflecting increased operating expenses despite a decrease in the change in fair value of contingent consideration.

In terms of operational metrics, iMDx's research and development expenses surged by 37% to $4.5 million for the second quarter, driven by ongoing development of its GraftAssure product line, which includes GraftAssureCore, GraftAssureIQ, and GraftAssureDx. Sales and marketing expenses also rose by 31% to $1.9 million, reflecting the company's efforts to ramp up its marketing activities related to its transplant business. General and administrative expenses increased by 9% to $2.9 million, primarily due to higher stock-based compensation and personnel-related costs.

The company reported a total of $17.8 million in cash and cash equivalents as of June 30, 2026, an increase from $11.6 million at the end of 2025. This increase was bolstered by a successful registered direct offering in February 2026, which generated approximately $26 million in gross proceeds. iMDx plans to utilize these funds for general corporate purposes and to support its research and development initiatives, particularly in the transplantation category. The company also has a remaining restricted cash balance of $972,000 related to a bank letter of credit.

iMDx continues to navigate a challenging market environment, with an accumulated deficit of $416.3 million as of June 30, 2026. The company is focused on obtaining regulatory approvals for its diagnostic tests, including the GraftAssureDx, which is currently under review by the FDA. Management anticipates ongoing operating losses and negative cash flows in the near future but believes it has sufficient liquidity to meet its operational needs for at least the next twelve months. The strategic partnership with Bio-Rad Laboratories, established in April 2024, remains a critical component of iMDx's growth strategy, as it collaborates on the development and commercialization of transplant products.